Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.33 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.33 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.33 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301304 | 1.00 | MAP4K4 (0.33) | MAP4K4MAPK9CSNK1DMINK1PRKD2 | |
| SCHEMBL8990186 | 1.00 | MAP4K4 (0.33) | MAP4K4MAPK9CSNK1DMINK1PRKD2 | |
| SCHEMBL3245463 | 0.81 | MAP4K4 (0.34) | MAP4K4MAPK9CSNK1DMINK1PRKD2 | |
| SCHEMBL3237339 | 0.81 | KDM4E (0.34) | MAP4K4MAPK9CSNK1DMINK1PRKD2 | |
| SCHEMBL12891156 | 0.73 | MET (0.36) | MAP4K4MAPK9CSNK1DMINK1PRKD2 | |
| SCHEMBL4817342 | 0.71 | MAP4K4 (0.38) | MAP4K4MAPK9CSNK1DMINK1PRKD2 | |
| SCHEMBL937870 | 0.71 | KDM4E (0.58) | MAP4K4MAPK9CSNK1DMINK1PRKD2 | |
| SCHEMBL17229853 | 0.66 | KDM4E (0.35) | MAP4K4MAPK9CSNK1DMINK1PRKD2 | |
| SCHEMBL4298715 | 0.65 | MET (0.34) | MAP4K4MAPK9CSNK1DMINK1PRKD2 | |
| SCHEMBL15359688 | 0.64 | APLNR (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188083-B2 | Triazolopyridazines | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | MAP4K4 24/4885MAPK9 101/4885CSNK1D 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.